Modest DP, Martens UM, Riera-Knorrenschild J, et al. - In a two-to-one randomized, controlled, open-label, phase II trial in individuals with untreated RAS wild-type (WT) metastatic colorectal cancer, a total of 63 individuals were randomized to the experimental arm and 33 to the control arm in order to examine the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI). The objective response rate (ORR) of the mFOLFOXIRI plus panitumumab arm surpassed 75% and was greater when contrasted with FOLFOXIRI. With the addition of panitumumab, improvement in the secondary resection rate was noted. In the study arms, progression-free survival was comparable, while in support of the panitumumab-containing arm, overall survival exhibited a trend. In conclusion, in individuals with RAS WT metastatic colorectal cancer, adding panitumumab to mFOLFOXIRI enhanced the ORR and rate of secondary resection of metastases and it designates a treatment choice in selected and fit cases in requirement of highly active first-line therapy.